Evidence map›Paper›PMID 21602175›Full record

ArticleInternational immunology2011

Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies.

Esther J Witsch, Georg Mahlknecht, Jean Wakim, Rotem Sertchook, Erez Bublil, Yosef Yarden, Michael Sela

Open access · bronzeAbstract read
In one paragraph

Article in International immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Tumor-targeting peptides from combinatorial libraries.Advanced drug delivery reviews · 2017
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Esther J WitschDepartment of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Georg Mahlknecht
Jean Wakim
Rotem Sertchook
Erez Bublil
Yosef Yarden
Michael Sela
Weizmann Institute of Science · IL

Funding

Next generation strategies to intercept ErbB signalingR37CA072981 · NCI · WEIZMANN INSTITUTE OF SCIENCE · PI YARDEN, YOSEF · 2005 to 2014
$2.3M
LATERAL VERSUS VERTICAL SIGNALING BY ERBB2 ONCOPROTEINR01CA072981 · NCI · WEIZMANN INSTITUTE OF SCIENCE · PI YARDEN, YOSEF NONE · 1997 to 2004
$953k
NCI NIH HHS CA072981
6 · The paper itself

Abstract

The erbb-2 gene receptor is often over-expressed in human cancer and its overexpression is accompanied by worse prognosis. Targeting erbb-2 gene with antibodies is an effective approach to curtail the progression of erbb-2 gene-expressing cancer types. Two monoclonal antibodies, L-26 and N-12, previously generated in our laboratory, have shown effective tumor inhibition in mice, especially when used in combination. Here, we describe novel peptide mimics of erbb-2 gene protein epitopes, also called mimotopes, that were selected from a constraint random 12-mer peptide phage library, specific for the antibodies L-26 and N-12. Initial sequencing analyses revealed little sequence conservation among the peptide mimotopes, and no sequence homology with the erbb-2 gene protein. However, computational analyses of the two groups of peptides, specific for L-26 and N-12, suggested different epitopes on the erbb-2 gene extracellular domain. In vitro assays showed that the phage displayed peptide mimotopes were specific to their respective antibodies. Selected cyclic peptide mimotopes, but not their corresponding linear equivalents, were able to inhibit binding of the antibodies L-26 and N-12 to the surface of erbb-2 gene-expressing cancer cells in a concentration-dependent manner. In line with this observation, phage-displayed cyclic peptides successfully competed in vitro with recombinant erbb-2 gene protein for binding to their respective antibodies L-26 or N-12. Consistent with the antibody inhibition experiments, we detected specific anti-erbb-2 gene antibodies following vaccination with KLH-coupled cyclic peptides but not with multiple antigenic linear peptides. Potentially, the selected peptides could serve as a starting point for the development of a vaccine against erbb-2 gene over-expressing cancer.

Indexed as

AnimalsAntibodies, MonoclonalAntibody SpecificityCell Line, TumorEpitopesErb-b2 Receptor Tyrosine KinasesHumansMiceMice, Inbred BALB CMolecular MimicryOligopeptidesPeptide LibraryAntibodies, MonoclonalEpitopesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesOligopeptidesPeptide Library

Identifiers

PMID21602175
PMCPMC3103390
OpenAlexW2107909123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.